News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Esperion Therapeutics, Inc. (ESPR) To Provide ETC-1002 Program Update; Fourth Quarter And Full Year 2013 Financial Results


2/27/2014 8:21:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Esperion Therapeutics, Inc. (NASDAQ:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced that it will host a conference call and webcast to provide program development updates and discuss financial results for the fourth quarter and full year ended Dec. 31, 2013. The webcast will take place following NASDAQ Market close on Wednesday, March 5, 2014 at 4:30 p.m. Eastern Time.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES